XML 21 R4.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Operating expenses:    
Research and development $ 8,767 $ 6,067
General and administrative 12,772 15,089
In-process research and development impairment charge 9,550 0
Severance costs related to Merger 0 1,883
Total operating expenses and operating loss (31,089) (23,039)
Non-operating income (expense):    
Change in fair value of warrant liability 5,300 0
Change in fair value of contingent consideration (3,032) 0
Loss on settlement of liability-classified warrants (727) 0
Gain on extinguishment of debt 766 0
Interest expense, net (266) (462)
Total non-operating income (expense), net 2,041 (462)
Loss before income taxes (29,048) (23,501)
Income tax expense (benefit) (1,378) 253
Net loss (27,670) (23,754)
Deemed dividend arising from beneficial conversion feature of convertible preferred stock (4,436) 0
Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision (8,654) 0
Impact of anti-dilution protection on liability-classified warrants (491) 0
Deemed dividend on conversion of 2015 Sely Note 0 (675)
Net loss attributable to common stockholders $ (41,251) $ (24,429)
Per share information:    
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) $ (3.15) $ (10.44)
Weighted-average common shares outstanding, basic and diluted (in shares) 13,077,140 2,340,368